OXAZEP is indicated for use as monotherapy or adjunctive therapy in the treatment of partial seizures in adults and as monotherapy in the treatment of partial seizures in aged 4 years and above with epilepsy, and as adjunctive therapy in children aged 2 years and above with partial seizures.
Mode of Action
The exact mechanism of oxcarbazepine for its anticonvulsant effect is unknown. It is known that the pharmacological activity of oxcarbazepine occurs primarily through its 10-monohydroxy metabolite (MHD). The MHD-induced blockade of voltage-sensitive sodium channels, resulting in stabilization of hyper-excited neuronal membranes, inhibition of repetitive neuronal discharges, and diminution of propagation of synaptic impulses.
OXAZEP is completely absorbed with no effect on the rate and extent of absorption of it. Tmax: 4.5 (range 3 to 13) hours; Volume of distribution- 49L OXAZEP is completely absorbed and extensively metabolized to its pharmacologically active 10-monohydroxy metabolite (MHD) by cytosolic enzymes. MHD is metabolized further by conjugation with glucuronic acid. The half-life of the parent is about 2 hours, while the half-life of MHD is about 9 hours, so that MHD is responsible for most anti-epileptic activity.
Dosage and Recommendation
For the Monotherapy Initial dose: 300mg orally twice a day, increased by increments of 300mg per day every third day as clinically indicated. Maintenance dose: 300 to 1,200 mg orally twice a day Maximum dose: 1,200 mg orally twice a day
Packing and Presentation
Available dose is 150/300/600mg tablet. Each strip contains 10 tablets